Cancer metabolomics is a rapidly evolving field that aims for a comprehensive dissection of the metabolic phenotypes and functional network of metabolites in human cancers. State of the art metabolomics tools have been developed and applied to studying cancer metabolism and developing metabolic targets for improved diagnosis, prognosis and therapeutic treatment of human cancers. Chapters are written by subject experts in the field of cancer metabolomics with cross-disciplinary contributions. Coverage includes advanced metabolomics technologies and methodologies, including chemical isotope labelling liquid chromatography - mass spectrometry, capillary ion chromatography - mass spectrometry, 2-D gas chromatography – mass spectrometry, capillary electrophoresis – mass spectrometry, nuclear magnetic resonance spectroscopy, shotgun lipidomics, tracer-based metabolomics, microbial metabolomics, mass spectrometry imaging for single cell metabolomics and functional metabolomics. In addition, the book highlights new discoveries in cancer metabolism such as hypoxia inducible factor pathway, isocitrate dehydrogenase 1 mutation and oncometabolites. Finally, contributors focus on the translational applications of metabolomics in human cancers such as glioma, head and neck cancer, and gastric cancer. This new volume will be a unique reference source for cancer researchers and promote applications of metabolomics in understanding cancer metabolism.

Antimicrobial resistance (AMR) is one of the deadliest threats to global public health. This book focuses on dynamics in the landscape of AMR while informing about the latest technologies and strategies to mitigate it. The menace of AMR in different niches, routes of penetration across various domains, socio-economic impact, and the need for a 'One Health' approach in mitigating AMR has been emphasized. Factors involved in AMR, underlying mechanisms, and pharmacometrics in developing antimicrobials are highlighted. Emphasis is given to emerging technologies that are sustainable, scalable, and applicable to the global community, such as big data analytics, bioactive agents, phage therapy, and nanotechnology. The book also explores current and alternative treatment strategies to combat AMR, emphasizing the use of nanoparticles to target pathogens and as a viable alternative to antibiotics.

This book serves as an excellent comprehensive material covering the current understandings and updates on antimicrobial resistance (AMR) and the use of medicinal plant resources for tackling it. Chapters cover important aspects of AMR and strategies to address this threatening issue with medicinal plants and their resources. One health perspectives for addressing AMR have been presented for the readers. Antimicrobial medicinal plant therapeutic resources including crude extracts, active fractions, pure molecules and essential oils, besides using them as functionalizing agents for nano-antimicrobials have been covered. Further, plant endophytes as a source of antimicrobial compounds have been discussed. Chapters cover both the bactericidal as well as resistance-reversal (or potentiating/ combinatorial therapies) potencies of medicinal plant resources. The book also focuses on how medicinal plant resources effectively target major determinants of AMR. Use of metabolomics in understanding and targeting AMR mechanisms and identifying potent phyto-therapeutics has been discussed as well. The book is a valuable read for both experienced and younger researchers working in the field of AMR and related fields in biomedicine, pharmacy, and clinical research.

Microbial Biofilms: Omics Biology, Antimicrobials and Clinical Implications is a comprehensive survey of microbial biofilms and their role in human health and disease with contributions from world renowned experts in molecular microbiology, proteomics, genomics, metabolomics and infectious diseases. The book is intended to serve as a guide for students, as well as a reference for researchers, clinicians and industry professionals. The chapters cover bacterial and fungal microbiomes, and the latest omics techniques organized in a clear and up-to-date manner. One of the highlights of this book is the comprehensive information on "omics of microbial biofilms". The chapters dedicated to metagenomics, proteomics and metabolomics are designed to provide a simple and holistic review of the current knowledge and, the applications of these techniques in the field of microbial biofilms. In addition to introductory chapters on microbial biofilms and their clinical implications, subsequent chapters delve into oral biofilms, their composition, and metagenomic diversity. Thereafter, mechanisms of drug resistance in microbial biofilms are reviewed, as well as the proteomic and metabolomic characterization of this resistance. The book includes a comprehensive discussion of persister cells and host–microbial interactions on mucosal surfaces. Finally, the book concludes with a summary of novel therapeutic approaches for biofilms such as synbiotics and biogenics.

Preceded by Genomics and clinical medicine / edited by Dhavendra Kumar. [First edition]. 2008.

Antibiotic resistance is a global health crisis. Misuse of antibiotics in humans, animals, food, and agriculture has compounded the situation. Bacterial infections have returned decades after medicines were first used. This book discusses antibiotic resistance and some of the organisms that pose immediate, serious, and alarming dangers. It highlights the need for a broader, more comprehensive approach to fighting bacterial infections, which may involve non-compound techniques (other than standard antibacterial drugs) that target bacteria or the host, such as antibodies, probiotics, phytobiotics, and vaccinations.

Precision Public Health is a new and rapidly evolving field, that examines the application of new technologies to public health policy and practice. It draws on a broad range of disciplines including genomics, spatial data, data linkage, epidemiology, health informatics, big data, predictive analytics and communications. The hope is that these new technologies will strengthen preventive health, improve access to health care, and reach disadvantaged populations in all areas of the world. But what are the downsides and what are the risks, and how can we ensure the benefits flow to those population groups most in need, rather than simply to those individuals who can afford to pay? This is the first collection of theoretical frameworks, analyses of empirical data, and case studies to be assembled on this topic, published to stimulate debate and promote collaborative work.